Association of preoperative duration of inotropy on prevalence of right ventricular failure following LVAD implantation.

ESC Heart Failure
Mina M BenjaminAsim Mohammed

Abstract

20% to 40% of left ventricular assist device (LVAD) device implantations are complicated by right ventricular (RV) failure that results in significant morbidity and mortality. We hypothesized that the duration on milrinone infusion is an independent risk factor for RV failure following LVAD implantation. Retrospective demographic, clinical and hemodynamic data were collected on all adults with ACC/AHA stage D heart failure on intravenous milrinone who underwent LVAD implantation between 2012 and 2019. Patients (n = 104) were divided into two groups, those on milrinone <30 days (STM, n = 55) vs. ≥30 (LTM, n = 49). The primary endpoint was the prevalence of RV failure (need for inotropic support for more than 14 days or RV assist device) within 30 days post-LVAD implantation. There were no significant differences between STM and LTM patients with respect to demographic, echocardiographic, right heart catheterization data, or baseline medications. The mean age of patients was 55.6 ± 12 years (70% male patients). Mean duration on milrinone was 13.7 vs. 81.0 days in STM and LTM, respectively. Forty-five (43.3%) patients developed RV failure. LTM had higher prevalence of RV failure with odds ratio (OR) = 5.04 (95% CI 2.18-11.68, P = ...Continue Reading

References

Nov 21, 1991·The New England Journal of Medicine·G D Curfman
Jan 1, 1989·Basic Research in Cardiology·A E Farah, C J Frangakis
Dec 22, 1999·The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation·B E JaskiW P Dembitsky
Mar 28, 2002·JAMA : the Journal of the American Medical Association·Michael S CuffeUNKNOWN Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) Investigato
Mar 26, 2003·Journal of the American College of Cardiology·G Michael FelkerUNKNOWN OPTIME-CHF Investigators
Jan 28, 2005·The Cochrane Database of Systematic Reviews·E AmsallemP Nony
Jan 10, 2006·The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation·Nicholas C DangYoshifumi Naka
Aug 3, 2007·Interactive Cardiovascular and Thoracic Surgery·Luisa SantambrogioMarco Maurelli
Dec 9, 2008·The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation·J Raymond FitzpatrickY Joseph Woo
Feb 6, 2010·The Journal of Thoracic and Cardiovascular Surgery·Robert L KormosUNKNOWN HeartMate II Clinical Investigators
Feb 26, 2010·The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation·Mark S SlaughterUNKNOWN HeartMate II Clinical Investigators
Mar 30, 2010·The American Journal of Cardiology·Stavros G DrakosPatrick W Fisher
Sep 3, 2010·Journal of Cardiovascular Translational Research·Ranjit JohnKenneth Liao
Jan 1, 2015·ASAIO Journal : a Peer-reviewed Journal of the American Society for Artificial Internal Organs·Athanasios TsiourisJeffrey A Morgan
Jan 7, 2015·Croatian Medical Journal·Marijan KoprivanacTomislav Mihaljević
Oct 12, 2015·The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation·Samuel B GoldfarbJosef Stehlik

❮ Previous
Next ❯

Citations

Dec 6, 2020·Pharmacotherapy·Ian B HollisDouglas J Jennings

❮ Previous
Next ❯

Software Mentioned

SAS

Related Concepts

Related Feeds

Artificial Heart & Ventricular Assist Devices

Total artificial hearts (TAH) and ventricular assist devices (VADs) provide cardiac support for patients with end-stage heart disease and have significantly improved the survival of these patients. Discover the latest research on Artificial Heart and Ventricular Assist Devices here.